The estimated Net Worth of Coelho Rogerio Vivaldi is at least $3.07 million dollars as of 21 July 2023. Dr Vivaldi owns over 5,528 units of Sigilon Therapeutics stock worth over $268,809 and over the last 10 years he sold SGTX stock worth over $2,002,850. In addition, he makes $802,372 as Pres et CEO & Director at Sigilon Therapeutics.
Sign up
Dr MBA SGTX stock SEC Form 4 insiders trading
Dr has made over 10 trades of the Sigilon Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 5,528 units of SGTX stock worth $106,359 on 21 July 2023.
The largest trade he's ever made was buying 41,667 units of Sigilon Therapeutics stock on 30 June 2014 worth over $250,002. On average, Dr trades about 6,198 units every 127 days since 2014. As of 21 July 2023 he still owns at least 11,963 units of Sigilon Therapeutics stock.
You can see the complete history of Dr Vivaldi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA biography
Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA is the Pres, CEO & Director at Sigilon Therapeutics.
What is the salary of Dr MBA?
As the Pres et CEO & Director of Sigilon Therapeutics, the total compensation of Dr MBA at Sigilon Therapeutics is $802,372. There are no executives at Sigilon Therapeutics getting paid more.
How old is Dr MBA?
Dr MBA is 57, he's been the Pres et CEO & Director of Sigilon Therapeutics since . There are 1 older and 4 younger executives at Sigilon Therapeutics. The oldest executive at Sigilon Therapeutics, Inc. is Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD, 72, who is the Co-Founder & Member of Scientific Advisory Board.
What's Dr MBA's mailing address?
Coelho's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO, CA, 92121.
Insiders trading at Sigilon Therapeutics
Over the last 4 years, insiders at Sigilon Therapeutics have traded over $2,000,000 worth of Sigilon Therapeutics stock and bought 2,018,493 units worth $31,039,916 . The most active insiders traders include Lilly & Co Eli, Lilly & Co Shenandoah Acqui... et John Cox. On average, Sigilon Therapeutics executives and independent directors trade stock every 139 days with the average trade being worth of $7,174,671. The most recent stock trade was executed by Lilly & Co Shenandoah Acqui... on 11 August 2023, trading 1,718,493 units of SGTX stock currently worth $25,639,916.
What does Sigilon Therapeutics do?
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Sigilon Therapeutics's logo look like?
Complete history of Dr Vivaldi stock trades at Minerva Neurosciences Inc, Crinetics Pharmaceuticals Inc, Sigilon Therapeutics et Viatris
Sigilon Therapeutics executives and stock owners
Sigilon Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA,
Pres, CEO & Director -
Dr. May Orfali M.B.A., M.D.,
Exec. VP & Chief Medical Officer -
Philip Ashton-Rickardt Ph.D.,
Chief Scientific Officer -
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
Co-Founder & Member of Scientific Advisory Board -
Dr. Daniel G. Anderson Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. José Oberholzer M.D.,
Co-Founder -
Matthew Kowalsky J.D.,
Chief Legal Officer -
Robert Windsor Jr., J.D.,
VP & Head of Investor Relations -
Josias Fantato De Pontes M.B.A.,
Acting CFO, Sr. VP, Principal Accounting Officer & Treasurer -
Dr. Arturo Vegas Ph.D.,
Co-Founder -
Dr. José Oberholzer M.D.,
Co-Founder -
Dr. Omid Veiseh Ph.D.,
Co-Founder -
Coelho Rogerio Vivaldi,
PRESIDENT AND CEO -
Glenn Reicin,
CHIEF FINANCIAL OFFICER -
Deya Corzo,
CHIEF MEDICAL OFFICER -
Devyn Smith,
CHIEF OPERATING OFFICER -
Lilly & Co Shenandoah Acqui...,
-
Douglas G. Cole,
-
Kavita Patel,
-
Stephen N. Oesterle,
-
Eric D. Shaff,
-
Ventures Fund V General Par...,
-
John Cox,
-
Lilly & Co Eli,
10% owner -
Robert R Ruffolo,
-
Brooke Story,
-
Philip Ashton Rickardt,
CHIEF SCIENTIFIC OFFICER -
Daniel Griffith Anderson,
-
Qing Sarah Yuan,
CTOO -
May Orfali,
CHIEF MEDICAL OFFICER -
Matthew Paul Kowalsky,
CHIEF OF STAFF AND CLO -
Josias Pontes,
CHIEF FINANCIAL OFFICER